Skip to main content

$1.035 (0%)

High

-

Low

-

Trades

-

Turnover

$0

Volume

0
17 May 2025 at 8:37am
Register to track BD1 and receive email alerts.
Subject
BD1 Ann: BARD1 Changes its Name to INOVIQ

BD1 Ann: Cleansing Notice - Issued of Four Shares - Resolution 5 AGM

BD1 Ann: Application for quotation of securities - BD1

BD1 Ann: Application for quotation of securities - BD1

BD1 Ann: Results of 2021 Annual General Meeting

BD1 Ann: AGM Presentation

BD1 Ann: New BARD1 Exosome Liquid Biopsy Project

BD1 Ann: Application for quotation of securities - BD1

BD1 Ann: Notification regarding unquoted securities - BD1

BD1 Ann: US Patent Issued - BARD1 Patent Family Lung Cancer Diagnosis

BD1 Ann: EXO-NET ANZSEV Presentation

BD1 Ann: BARD1 Presenting at Bell Potter Healthcare Conference

BD1 Ann: EXO-NET Presented at Virtual ANZSEV Symposium

BD1 Ann: Jobkeeper Payment Notification

BD1 Ann: Notice of Annual General Meeting/Proxy Form

BD1 Ann: Ceasing to be a substantial holder

BD1 Ann: Appendix 4G and Corporate Governance Statement

BD1 Ann: Appendix 4C & Quarterly Activities Report

BD1 Ann: Change of Director's Interest - Philip Powell

BD1 Ann: Amended Remuneration Table Directors Report

BD1 Ann: Notice required under listing rule 3.13.1

BD1 Ann: Notification of cessation of securities - BD1

BD1 Ann: 2021 Annual Report

BD1 Ann: BARD1 Appoints New CSO

BD1 Ann: Notification of cessation of securities - BD1

BD1 Ann: Appendix 4E and Preliminary Financial Report

BD1 Ann: Change in substantial holding

BD1 Ann: Change of Director's Interest - Powell

BD1 Ann: Change of Director's Interest - Dr Geoffrey Cumming

BD1 Ann: Change of Director's Interest - Johnston

BD1 Ann: Notification of cessation of securities - BD1

BD1 Ann: Appendix 2A

BD1 Ann: BARD1 Share Purchase Plan Completed Oversubscribed

BD1 Ann: Proof-of-Concept for SubB2M ELISA-Based Ovarian Cancer Test

BD1 Ann: BARD1 LODGES SPP AND OPTIONS PROSPECTUS

BD1 Ann: Appendix 4C & Quarterly Activities Report

BD1 Ann: Appendix 2A

BD1 Ann: BARD1 Collaborator Uni of QLD Announces Ovarian Cancer Data

BD1 Ann: Updated Investor Presentation

BD1 Ann: Terms of issue of Options

BD1 Ann: Investor Presentation

BD1 Ann: Appendix 3B

BD1 Ann: BARD1 $15m Placement to Accelerate Cancer Diagnostic Program

BD1 Ann: Trading Halt

BD1 Ann: BARD1 Investor Presentation

BD1 Ann: BARD1 Autoantibody Test Results for Ovarian Cancer Published

BD1 Ann: SubB2M Breast Cancer Test Manuscript Submitted

BD1 Ann: Update on Legal Proceedings

BD1 Ann: R&D Tax Incentive Refund Received

BD1 Ann: BARD1 Demonstrates Feasibility of SubB2M-Based IHC Test

Register to track BD1 and receive email alerts.

Similar Companies

AHX
CAJ
HLA
HLS
IDX
RHY
SHL
SLA
TTB